Harry Dolstra

12PUBLICATIONS
49CO-AUTHORS
Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Apr 03, 2026
Sialic acid cis-ligand dynamics modulate Siglec-7 and -9 function and affect Siglec-7/9 co-blockade to potentiate natural killer cell anti-tumor activity.

Jesper van Eck van der Sluijs, Anne H C Valk, Eline J H van Houtum

|Feb 17, 2025
IL-15 transpresentation by ovarian cancer cells improves CD34+ progenitor-derived NK cell's anti-tumor functionality.

M Vidal-Manrique, T Nieuwenstein, L Hooijmaijers

|Sep 20, 2023
Human CD34+-derived complete plasmacytoid and conventional dendritic cell vaccine effectively induces antigen-specific CD8+ T cell and NK cell responses in vitro and in vivo.

Jesper van Eck van der Sluijs, Diede van Ens, Jolanda Brummelman

|Oct 07, 2021
CD34+ progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rgnull mice.

Jolien M R Van der Meer, Paul K J D de Jonge, Anniek B van der Waart

|Sep 15, 2021
Correction to: IL‑15 superagonist N‑803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor‑derived NK cells.

J M R Van der Meer, R J A Maas, K Guldevall

|Apr 02, 2021
Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses.

Jesper van Eck van der Sluijs, Diede van Ens, Soley Thordardottir

Pageof 2

Frequent Collaborators

9 joint publications

Anniek B van der Waart

9 joint publications

Willemijn Hobo

9 joint publications

Joop H Jansen

8 joint publications

Nicolaas Pm Schaap